Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Consensus "Moderate Buy": Five analysts average a "Moderate Buy" rating (1 sell, 1 hold, 2 buy, 1 strong buy) with a 12‑month mean target of $18.50 and individual targets up to $21.
• Notable insider selling: COO Nathan Dowden and CFO Kory Wentworth each sold ~11.9k and ~11.4k shares on March 10; insiders have sold 39,475 shares (~$508k) in the past three months while still owning 7.59% of the stock.
• Mixed quarterly results and stock metrics: The company beat EPS estimates (loss of $0.94 vs. -$1.32 expected) but missed revenue ($1.3M vs. $7.41M), with shares around $12.62, market cap ~$483M and a 52‑week range of $4.93–$13.65.

Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $18.50.

A number of analysts have recently weighed in on TRDA shares. Wall Street Zen cut shares of Entrada Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Oppenheimer began coverage on shares of Entrada Therapeutics in a report on Wednesday, January 28th. They issued an "outperform" rating and a $21.00 target price on the stock. Weiss Ratings reissued a "sell (d)" rating on shares of Entrada Therapeutics in a research report on Friday. Finally, Guggenheim upgraded shares of Entrada Therapeutics to a "strong-buy" rating in a report on Wednesday, February 11th.

Insider Activity

In related news, COO Nathan J. Dowden sold 11,894 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $13.05, for a total transaction of $155,216.70. Following the completion of the sale, the chief operating officer owned 198,588 shares in the company, valued at $2,591,573.40. This represents a 5.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Kory James Wentworth sold 11,388 shares of the firm's stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $13.02, for a total value of $148,271.76. Following the completion of the sale, the chief financial officer directly owned 121,510 shares in the company, valued at $1,582,060.20. This trade represents a 8.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 39,475 shares of company stock valued at $508,069 in the last three months. 7.59% of the stock is owned by insiders.

Hedge Funds Weigh In On Entrada Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its position in shares of Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company's stock worth $4,245,000 after acquiring an additional 42,479 shares during the period. Intech Investment Management LLC increased its position in shares of Entrada Therapeutics by 15.7% during the second quarter. Intech Investment Management LLC now owns 17,702 shares of the company's stock valued at $119,000 after purchasing an additional 2,397 shares during the period. Rhumbline Advisers increased its position in shares of Entrada Therapeutics by 8.3% during the second quarter. Rhumbline Advisers now owns 39,095 shares of the company's stock valued at $263,000 after purchasing an additional 2,982 shares during the period. American Century Companies Inc. raised its stake in shares of Entrada Therapeutics by 10.8% in the second quarter. American Century Companies Inc. now owns 75,094 shares of the company's stock valued at $505,000 after purchasing an additional 7,301 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of Entrada Therapeutics by 23.4% in the second quarter. Prudential Financial Inc. now owns 28,340 shares of the company's stock valued at $190,000 after purchasing an additional 5,370 shares in the last quarter. Institutional investors own 86.39% of the company's stock.

Entrada Therapeutics Stock Performance

Shares of NASDAQ TRDA opened at $12.62 on Wednesday. The business's 50-day simple moving average is $11.69 and its 200-day simple moving average is $9.55. Entrada Therapeutics has a 52 week low of $4.93 and a 52 week high of $13.65. The firm has a market cap of $483.09 million, a price-to-earnings ratio of -3.65 and a beta of -0.12.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating analysts' consensus estimates of ($1.32) by $0.38. The business had revenue of $1.30 million for the quarter, compared to the consensus estimate of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. As a group, equities research analysts forecast that Entrada Therapeutics will post 1.12 earnings per share for the current year.

Entrada Therapeutics Company Profile

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.